(Q40408945)

20 September 2017

title

Selenium-based drug design: rationale and therapeutic potential (English)

1 reference

20 September 2017

May SW

1

1 reference

20 September 2017

language of work or name

English

0 references

publication date

1 July 1999

1 reference

Expert Opinion on Investigational Drugs

20 September 2017

published in

1 reference

20 September 2017

volume

8

1 reference

20 September 2017

issue

7

1 reference

20 September 2017

page(s)

1017-1030

1 reference

Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group.

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.7.1017

Plasma selenium levels in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.7.1017

Seleno-organic compounds and the therapy of hydroperoxide-linked pathological conditions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.7.1017

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.7.1017

The role of selenium peroxidases in the protection against oxidative damage of membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.7.1017

Selenoprotein P associates with endothelial cells in rat tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.7.1017

Selenocysteine, identified as the penultimate C-terminal residue in human T-cell thioredoxin reductase, corresponds to TGA in the human placental gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.7.1017

Rat and calf thioredoxin reductase are homologous to glutathione reductase with a carboxyl-terminal elongation containing a conserved catalytically active penultimate selenocysteine residue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.7.1017

Reduction of dehydroascorbate to ascorbate by the selenoenzyme thioredoxin reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.7.1017

Selenocysteine: the 21st amino acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.7.1017

Molecular cloning and characterization of a mitochondrial selenocysteine-containing thioredoxin reductase from rat liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.7.1017

Synthesis of 5-methylaminomethyl-2-selenouridine in tRNAs: 31P NMR studies show the labile selenium donor synthesized by the selD gene product contains selenium bonded to phosphorus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.7.1017

Monoselenophosphate: synthesis, characterization, and identity with the prokaryotic biological selenium donor, compound SePX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.7.1017

Autoantibodies against a serine tRNA-protein complex implicated in cotranslational selenocysteine insertion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.7.1017

Acid-volatile selenium formation catalyzed by glutathione reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.7.1017

On the nature of selenium toxicity and carcinostatic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.7.1017

Metabolic fate of selected selenium compounds in laboratory animals and man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.7.1017

Interpretation of the methylene blue reduction test of human plasma and the possible cancer protecting effect of selenium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.7.1017

Cancer mortality correlation studies--III: statistical associations with dietary selenium intakes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.7.1017

Selenium in forage crops and cancer mortality in U.S. counties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.7.1017

Selenium. Mechanistic aspects of anticarcinogenic action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.7.1017

Vitamin/mineral supplementation and cancer risk: international chemoprevention trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.7.1017

Rheumatoid arthritis and metal compounds--perspectives on the role of oxygen radical detoxification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.7.1017

Interaction of dopamine beta-mono-oxygenase with substituted imidazoles and pyrazoles. Catalysis and inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.7.1017

Novel antihypertensives targeted at dopamine .beta.-monooxygenase: turnover-dependent cofactor depletion by phenylaminoethylselenide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.7.1017

Clinical use of beta-adrenoceptor blockade in systemic hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.7.1017

The mechanism of thioredoxin reductase from human placenta is similar to the mechanisms of lipoamide dehydrogenase and glutathione reductase and is distinct from the mechanism of thioredoxin reductase from Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.7.1017

A new selenoprotein from human lung adenocarcinoma cells: purification, properties, and thioredoxin reductase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.7.1017

Adult T-cell leukemia-derived factor/thioredoxin, produced by both human T-lymphotropic virus type I- and Epstein-Barr virus-transformed lymphocytes, acts as an autocrine growth factor and synergizes with interleukin 1 and interleukin 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.7.1017

The conversion of 2-β-D-ribofuranosylthiazole-4-carboxamide to an analogue of NAD with potent IMP dehydrogenase-inhibitory properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.7.1017

Comparative in vitro studies of Tiazofurin and a selenazole analog.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.7.1017

Tiazofurin: a new antitumor agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.7.1017

Antiviral and immunomodulating inhibitors of experimentally-induced Punta Toro virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.7.1017

Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial. Ebselen Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.7.1017

Neuroprotective efficacy of ebselen, an anti-oxidant with anti-inflammatory actions, in a rodent model of permanent middle cerebral artery occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.7.1017

Ebselen, a selenium-containing redox drug, releases zinc from metallothionein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.7.1017

10.1517/13543784.8.7.1017

21 January 2018

Identifiers

DOI

1 reference

20 September 2017

1 reference